Alvotech (ALVO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Alvotech Stock (ALVO) Company Profile

Healthcare (1200)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ALVO's Discussions on Twitter

Vergleichen Sie ALVO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALVO Alvotech	11.68	3.54B	306.77M	-618.38M	-343.00M	-1.97
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

Alvotech Stock (ALVO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-29	Hochstufung	Barclays	Equal Weight → Overweight
2023-10-20	Hochstufung	Citigroup	Sell → Neutral
2023-09-21	Eingeleitet	Barclays	Equal Weight
2022-09-07	Eingeleitet	Morgan Stanley	Equal-Weight
2022-09-06	Herabstufung	Citigroup	Buy → Sell
2022-07-26	Eingeleitet	Citigroup	Buy

Alle ansehen

Alvotech Aktie (ALVO) Neueste Nachrichten

Finanzdaten der Alvotech-Aktie (ALVO)

Alvotech (ALVO)

Alvotech Stock (ALVO) Company Profile

Vergleichen Sie ALVO mit anderen Aktien

Alvotech Stock (ALVO) Upgrades & Downgrades

Alvotech Aktie (ALVO) Neueste Nachrichten

Alvotech’s Eylea Biosimilar ‘Keeps In Mind’ US Patent Landscape - Citeline

Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth hurdles - Investing.com

Alvotech (ALVO) Shares Gap Down to $11.94 on Nov 22 - GuruFocus.com

Alvotech’s Position In The Coming Biosimilar Gold Rush (NASDAQ:ALVO) - Seeking Alpha

Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates - MSN

Alvotech Third Quarter 2024 Earnings: US$0.041 loss per share (vs US$0.81 loss in 3Q 2023) - Yahoo Finance

Earnings call: Alvotech reported revenues of $128 million - Investing.com India

Alvotech (ALVO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - Investing.com Canada

Alvotech Reports Strong Revenue Growth in 2024 - TipRanks

Earnings call: Alvotech reported revenues of $128 million By Investing.com - Investing.com Canada

Alvotech earnings missed, revenue fell short of estimates By Investing.com - Investing.com Nigeria

Alvotech earnings missed, revenue fell short of estimates - Investing.com India

Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges By Investing.com - Investing.com Australia

Alvotech : First 9 Months Earnings and Business Update 2024 - Marketscreener.com

Alvotech Showcases Strong Financial Growth and Expansion - TipRanks

Alvotech Reports Financial Results for the First Nine Months of 2024 - The Manila Times

Alvotech's SWOT analysis: biosimilars powerhouse stock faces growth challenges - Investing.com

EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab) - JD Supra

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - The Manila Times

Alvotech Attending Citi's Global Healthcare Conference on - GlobeNewswire

Alvotech to Present at Citi and Evercore Healthcare Conferences in December | ALVO Stock News - StockTitan

ADVANZ PHARMAEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi - Marketscreener.com

EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi - BioPharma-Reporter.com

EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for its biosimilar of J&J’s Simponi - BioPharma-Reporter.com

EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA - Pharmaceutical Technology

Alvotech application for Simponi biosimilar accepted by EMA - MSN

Alvotech’s AVT05 Biosimilar Application Accepted by EMA - TipRanks

European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - The Manila Times

European Medicines Agency Confirms Acceptance of Marketing - GlobeNewswire

Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar - JD Supra

Alvotech Petitions FDA To Deny Interchangeability For Rival Stelara Biosimilars - Citeline News & Insights

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - The Manila Times

Alvotech to Report Financial Results for the First Nine - GlobeNewswire

Alvotech, Teva obtain FDA nod for new Selarsdi indication - Drug Store News

Exploring High Growth Tech Stocks In The US October 2024 - Simply Wall St

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - StockTitan

Alvotech Meeting Investors and Presenting at the Jefferies - GlobeNewswire

FDA approves Alvotech and Teva’s SELARSDI for new indications - MSN

Alvotech's SWOT analysis: biosimilar powerhouse stock faces growth hurdles - Investing.com

Teva, Alvotech get expanded FDA approval for Stelara biosimilar - MSN

Teva, Alvotech get expanded FDA approval for Stelara biosimilar (NYSE:TEVA) - Seeking Alpha

Alvotech and Teva Secure FDA Approval for SELARSDI - TipRanks

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) - The Manila Times

Teva, Alvotech announce U.S. FDA approval of presentation of SELARSDI - TipRanks

Alvotech and Teva Announce U.S. FDA Approval of Additional - GlobeNewswire

Finanzdaten der Alvotech-Aktie (ALVO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ALVO